Pulmatrix, Inc. (PULM) financial statements (2021 and earlier)

Company profile

Business Address 99 HAYDEN AVENUE
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments32352724232832
Cash and cash equivalents32352724232832
Receivables010 7  
Prepaid expense0110001
Deferred costs0000000
Other undisclosed current assets0112001
Total current assets:33372926312933
Noncurrent Assets
Operating lease, right-of-use asset12201  
Property, plant and equipment0000000
Intangible assets, net (including goodwill)4444444
Goodwill4444444
Restricted cash and investments0000000
Total noncurrent assets:6665544
TOTAL ASSETS:38433531363337
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3345322
Accounts payable1101111
Accrued liabilities2234311
Deferred revenue441012139 
Debt0   1  
Other undisclosed current liabilities1311  11
Total current liabilities:8111517171213
Noncurrent Liabilities
Long-term debt and lease obligation111    
Operating lease, liability111    
Liabilities, other than long-term debt685786 
Deferred revenue685786 
Other undisclosed noncurrent liabilities      6
Total noncurrent liabilities:7977866
Total liabilities:15192124251819
Stockholders' equity
Stockholders' equity attributable to parent2324147111518
Common stock0000000
Additional paid in capital258255235227226226226
Accumulated deficit(234)(232)(221)(220)(215)(211)(208)
Total stockholders' equity:2324147111518
TOTAL LIABILITIES AND EQUITY:38433531363337

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Gross profit:2443215
Operating expenses(5)(6)(5)(7)(6)(5)(13)
Operating loss:(3)(1)(1)(5)(4)(4)(8)
Nonoperating income (expense)(10)000(0)00
Investment income, nonoperating 000 0 
Other nonoperating income (expense)  (0)(0)  0
Loss before gain (loss) on sale of properties:(12)(1)(1)(5)(4)(4)(8)
Other undisclosed net income    0  
Net loss:(12)(1)(1)(5)(4)(4)(8)
Other undisclosed net income (loss) attributable to parent9(9)     
Net loss available to common stockholders, diluted:(3)(11)(1)(5)(4)(4)(8)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(12)(1)(1)(5)(4)(4)(8)
Comprehensive loss, net of tax, attributable to parent:(12)(1)(1)(5)(4)(4)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: